Developing skills to produce
biosimilar drugs in Serbia, as well as consolidating the
cooperation relationship of the Friuli Venezia Giulia Region
with that territory. These are the goals of the MabTher project,
the launch of which was formalized today by Regional Labor
Councillor Alessia Rosolen and ICGEB Director General Lawrence
Banks.
The initiative involves transferring knowledge from ICGEB to
the Serbian Institute for the Application of Nuclear Energy to
develop and produce the Mab biosimilar drug Trastuzumab, a
monoclonal antibody used to treat breast and stomach cancer.
Serbian researchers and officials, the FVG Region informs,
will be supported in acquiring the necessary skills for
technology transfer and training in the Biotechnology
development unit of Icgeb. Technology transfer will be
supervised by ICGEB staff, who will assist Serbian researchers
in replicating the process of making Trastuzumab in Serbia using
local facilities and industries. Banks remarked that building
local manufacturing capacity and skills is a cornerstone for
creating local employment, wealth, and stability.
This pilot initiative involves the transfer of technologies
that ICGEB has developed over many years of optimization so that
biotherapeutics that meet all Food and Drug Administration (FDA)
and European Pharmacopoeia standards can be transferred to the
Serbian industry. These products can then be produced and
marketed locally at a lower price than standard international
supply chains, thus making health care more affordable and
creating jobs at the same time. "Sharing the knowledge and
production techniques of these drugs with other nations of our
territorial area, such as the Balkans - Rosolen said - makes it
possible to overcome the inequalities produced by the
pharmaceutical market and produces positive effects,
strengthening international cooperation and collaboration."
ALL RIGHTS RESERVED © Copyright ANSA
